Search Within

Shanu Modi

  1. "2022"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (8)
  3. Review (2)
  4. Correspondence (1)
Groups
  1. Breast Medicine Service (19)
  2. Department of Medicine (19)
  3. Solid Tumor Oncology Division (19)
  4. Biostatistics Service (5)
  5. Epidemiology and Biostatistics (5)
  6. GSK Faculty (5)

More Groups

People
  1. Pedram Razavi (4)
  2. Sujata Patil (4)
  3. Ayca Gucalp (3)
  4. Jacqueline Bromberg (3)
  5. Kathryn Beal (3)
  6. Neil Iyengar (3)

More People

Years
  1. 2022 (19)
Publications
  1. Annals of Oncology (2)
  2. Cancer Research (2)
  3. Journal of Clinical Oncology (2)
  4. New England Journal of Medicine (2)
  5. npj Breast Cancer (2)
  6. Breast Cancer Research and Treatment (1)

More Publications

Publishers
  1. American Association for Cancer Research (3)
  2. Oxford University Press (3)
  3. American Society of Clinical Oncology (2)
  4. Elsevier Inc. (2)
  5. Massachusetts Medical Society (2)
  6. Nature Publishing Group (2)

More Publishers

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Meeting Abstract

    Liu, B.; Drago, J. Z.; Rao, Y.; Pereira, P. R.; Safonov, A.; Marra, A.; Ahmed, M. S.; Modi, S.; Reis, J. S.; Montemurro, F.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
    Meeting Abstract

    Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N. T.; Chae, Y. S.; Lee, K. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Multifocal, durable and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
    Meeting Abstract

    Tosi, U.; Moss, N.; Santomasso, B.; Beal, K.; Modi, S.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788
    Meeting Abstract

    Hurvitz, S. A.; Kalinsky, K.; Tripathy, D.; Sledge, G.; Gradishar, W. J.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; Frentzas, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Meeting Abstract

    Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis
    Journal Article

    Jerusalem, G.; Park, Y. H.; Yamashita, T.; Hurvitz, S. A.; Modi, S.; Andre, F.; Krop, I. E.; FarreĢ, X. G.; You, B.; Saura, C.; more...
    Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens
    Meeting Abstract

    Lu, J. M.; Kalinsky, K.; Tripathy, D.; Sledge, G. W.; Gradishar, W. J.; O'Regan, R.; O'Shaughnessy, J.; Modi, S.; Park, H.; McCartney, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in HER2-low breast cancer - The authors reply
    Correspondence

    Modi, S.; Gambhire, D.; Cameron, D.
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save